Related Experiment Video
Updated: Aug 15, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
[Impact of stress on hepatic lipid and carbohydrate metabolism, prevention]
Abstract:
An oligomer proantocyanidine complex (OPCC) isolated from the aqueous-and-alcoholic extract Kalifen and a polyphenol complex (PPC) isolated from the eleutherococcus extract were tested for their effects on carbohydrate and lipid metabolism in the rat liver under acute stress caused by hanging up of the animals by the cervical fold for 22 hours. This acute stress was accompanied by decreases in aerobic glycolysis and pentose cycle and by an increase in lipolysis. Hepatic etherifying function impaired. Lipids became predominant energy substrates. The administration of OPCC and PPC during stress promoted the preservation of carbohydrate metabolic reactions (gluconeogenesis, pentosephosphate pathway, Krebs cycle) and to the decrease of lipolysis. OPCC was shown to have stress-protective properties and to be able to diminish adrenal hypertrophy, to increase the production of oxidized equivalents (NAD+), and to enhance the activity of G-6-PDH in the rat liver. The complex is superior to the well-known antistress agent eleutherococcus, which makes it possible to regard these drugs as possible promising drugs in preventive and rehabilitative medicine.
Related Concept Videos
Overview of Carbohydrate Metabolism
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Atherosclerosis III: Management

